logo
Article

Standards of Care in Diabetes - 2026

03 Feb, 2026
Cardiology

Summary:

·       The American Diabetes Association (ADA) 2026 Standards of Care, released in December 2025, represents a significant shift toward "technology-first" care and more aggressive weight management.

·       The update focuses on removing barriers to advanced tools and expanding the use of newer medications (like GLP-1 and GIP/GLP-1 receptor agonists) for conditions beyond simple blood sugar control.

·       The update further solidifies the role of SGLT2 inhibitors (SGLT2i) as foundational therapy, shifting the focus from glucose management to "mechanism-driven" cardiometabolic protection.

·       Irrespective of A1C: SGLT2i are now recommended for all patients with Type 2 Diabetes and heart failure, regardless of their current blood sugar control or background metformin use.

·       The 2026 guidelines explicitly support SGLT2i use across the entire spectrum of heart failure, including HFpEF (preserved ejection fraction) and HFmrEF (mildly reduced ejection fraction), where they were previously less emphasized.

·       Inpatient Initiation: A new "Grade A" recommendation strongly supports initiating or continuing SGLT2i during hospitalization for heart failure, provided there are no contraindications (e.g., euglycemic DKA risk).

·       The ADA now aligns more closely with cardiology societies (ACC/AHA) by positioning SGLT2i as one of the four essential pillars for HFrEF management.

·       SGLT2i are recognized for their ability to stabilize renal function and potassium levels, which helps patients better tolerate other life-saving cardiac meds like ACE inhibitors or MRAs.

·       For patients with Type 2 Diabetes and chronic kidney disease (uACR ≥100 mg/g), the 2026 standards suggest considering the simultaneous initiation of an SGLT2i and a non-steroidal MRA (like finerenone) to provide rapid cardiorenal protection.

·       For those with established heart failure or high CVD risk, the systolic blood pressure target has been lowered to <120 mmHg (down from <130 mmHg) if it can be achieved safely.

SGLT2i are increasingly recommended as an early add-on for patients who do not yet have heart failure but are at high risk (Stage B Heart Failure), specifically to prevent the first hospitalization for heart failure.

Reference:
American Diabetes Association Professional Practice Committee for Diabetes*; Summary of Revisions: Standards of Care in Diabetes—2026. Diabetes Care 1 January 2026; 49 (Supplement_1): S6–S12. https://doi.org/10.2337/dc26-SREV

For more information:
https://diabetesjournals.org/care/article/49/Supplement_1/S6/163930/Summary-of-Revisions-Standards-of-Care-in-Diabetes

For Healthcare Professionals

Contact Us

eva logo

We empower the fight for health and well being as a human right.

Subscribe for our latest news and updates

For adverse events reporting, please contact us on

PV.Report@evapharma.com

© 2026 Eva Pharma All Rights Reserved - شركة ايفا فارما للادوية و المستلزمات الطبية